Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...

The experimental therapy Bravyl significantly reduced the spread of toxic TDP-43 protein clumps in a cell model of ALS.

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

But rather than raising awareness, a recent storyline on the long-running program may have sowed seeds of doubt about living ...

Neurizon has reported positive eight-month interim data from its open-label extension study in patients with ALS (motor ...

Amyotrophic lateral sclerosis (ALS) is a rare neurological disorder that affects specific nerve cells in the spinal cord known as motor neurons. Symptoms involve issues with swallowing and speech ...

A promising ultrasound therapy to potentially restore brain function in people with Alzheimer's disease has been licenced to ...

VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces ...

Maxim downgraded NeuroSense (NRSN) to Hold from Buy. The firm cites the company having received feedback from the FDA regarding the Phase trial 3 design for PrimeC to treat amyotrophic lateral ...

The global amyotrophic lateral sclerosis treatment market size was US$ 637.2 million in 2021. The global amyotrophic lateral sclerosis treatment market is forecast to grow to US$ 918 million by 2030, ...